Clinical trials: Bortezomib
Multiple Myeloma
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
This is a phase I/II multicenter, open label, nonrandomized study for patients with Multiple Myeloma (MM) who will receive treatment with carfilzomib in place of bortezomib using the same bortezomib-containing combination regimen…
- Trial name
- NCT01365559
- Testing
- Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Tumors, Non-Hodgkins's Lymphoma
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
This is an open-label, randomized, multiple-dose, multicenter Pharmacokinetics drug-drug interaction study in patients with advanced solid tumors, including non-Hodgkin's lymphoma, who are in need of anti-tumor therapy.
- Trial name
- NCT00298779
- Testing
- omeprazole and bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
The purpose of this study is determination of the event-free survival with and without Bortezomib consolidation therapy from the day of the first chemotherapeutic, myeloma-specific therapy measure, up to the occurrence of…
- Trial name
- NCT00416273
- Testing
- Bortezomib, No intervention
- Where
- 38 sites in Germany
- Volunteers
- 217 people
- Sponsor
- Janssen-Cilag G.m.b.H
Multiple Myeloma
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
The purpose of this study is to allow patients to receive VELCADE™ (bortezomib) for Injection who experienced progressive disease(PD) while receiving high-dose dexamethasone from the M34101-039 study.
- Trial name
- NCT00063726
- Testing
- bortezomib
- Where
- 76 sites in United States, Austria and 11 more
- Volunteers
- 600 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lymphoma, Mantle-Cell
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.
- Trial name
- VEGA (NCT05564052)
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- 66 sites in Brazil, Czechia and 11 more
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
- Trial name
- CARTITUDE-4 (NCT04181827)
- Testing
- Cilta-cel, Pomalidomide, Bortezomib
- Where
- 88 sites in United States, Australia and 14 more
- Volunteers
- 419 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM
The purpose of this study is to compare the safety and efficacy of Lenalidomide versus Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly diagnosed multiple myeloma.
- Trial name
- ARUMM (NCT02112175)
- Testing
- Lenalidomide
- Where
- 73 sites in Belgium, France and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene
Multiple Myeloma
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
This is a multi-center, open-label, single arm, non-comparative phase II trial, designed to evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with Multiple Myeloma (MM) double…
- Trial name
- NCT03117361
- Testing
- plitidepsin, Bortezomib, Dexamethasone
- Where
- 13 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- PharmaMar
Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can help treat participants who are newly diagnosed and previously untreated for…
- Trial name
- LINKER-AL1 (NCT07901725)
- Testing
- Linvoseltamab, Daratumumab, Bortezomib
- Volunteers
- 382 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen.
- Trial name
- NCT03984097
- Testing
- TAK-079, Lenalidomide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Takeda
Multiple Myeloma
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past.
- Trial name
- NCT01602224
- Testing
- Dexamethasone, Bortezomib, Tabalumab
- Where
- 57 sites in United States, Brazil and 13 more
- Volunteers
- 220 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in…
- Trial name
- NCT01359657
- Testing
- Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4…
- Trial name
- SEQUENTIAL (NCT00908232)
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 42 sites in France, Germany and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV
Multiple Myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
- Trial name
- NCT06152575
- Testing
- Elranatamab, Elotuzumab, Pomalidomide
- Where
- 270 sites in United States, Argentina and 25 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Advanced Non-Small Cell Lung Cancer, Other Solid Tumors
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
The purpose of this study is to evaluate how safe VELCADE (PS-341) is when given with Taxotere (Docetaxel) to patients with non-small cell lung cancer or other solid tumors, and also to see what effects (good and bad) it has on…
- Trial name
- NCT00064636
- Testing
- VELCADE TM (bortezomib) for Injection, or PS-341
- Volunteers
- 46 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma
The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is commonly used currently in South Korea as a first-line treatment for treatment-naïve patients with multiple myeloma who are ineligible…
- Trial name
- VISION (NCT04151615)
- Where
- 24 sites in South Korea
- Volunteers
- 203 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Multiple Myeloma
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously…
- Trial name
- NCT00111319
- Testing
- bortezomib
- Where
- United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment.
- Trial name
- aMMbition (NCT06577025)
- Testing
- Cilta-cel, Talquetamab, Daratumumab
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 43 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.
- Trial name
- NCT00833560
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 34 sites in Germany
- Volunteers
- 401 people
- Sponsor
- Janssen-Cilag G.m.b.H